| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2263 | 2015 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 558 | 2020 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 388 | 2017 |
| Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ... European urology 76 (4), 469-478, 2019 | 342 | 2019 |
| Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ... The Journal of clinical investigation 129 (1), 192-208, 2019 | 334 | 2019 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 227 | 2020 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 204 | 2018 |
| Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer D Lorente, D Olmos, J Mateo, D Bianchini, G Seed, M Fleisher, DC Danila, ... European urology 70 (6), 985-992, 2016 | 155 | 2016 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 141 | 2018 |
| Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC) J Welti, A Sharp, W Yuan, D Dolling, D Nava Rodrigues, I Figueiredo, ... Clinical Cancer Research 24 (13), 3149-3162, 2018 | 131 | 2018 |
| Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis MB Lambros, G Seed, S Sumanasuriya, V Gil, M Crespo, M Fontes, ... Clinical Cancer Research 24 (22), 5635-5644, 2018 | 108 | 2018 |
| Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA) N Mehra, D Dolling, S Sumanasuriya, R Christova, L Pope, S Carreira, ... European urology 74 (3), 283-291, 2018 | 106 | 2018 |
| Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells R Ferraldeschi, J Welti, MV Powers, W Yuan, T Smyth, G Seed, ... Cancer research 76 (9), 2731-2742, 2016 | 95 | 2016 |
| Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ... Cancer discovery 11 (11), 2812-2827, 2021 | 92 | 2021 |
| Advanced prostate cancer with ATM loss: PARP and ATR inhibitors A Neeb, N Herranz, S Arce-Gallego, S Miranda, L Buroni, W Yuan, A Athie, ... European urology 79 (2), 200-211, 2021 | 85 | 2021 |
| Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts D Lorente, D Olmos, J Mateo, D Dolling, D Bianchini, G Seed, P Flohr, ... Annals of oncology 29 (7), 1554-1560, 2018 | 73 | 2018 |
| Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer A Sharp, JC Welti, MBK Lambros, D Dolling, DN Rodrigues, L Pope, ... European urology 76 (5), 676-685, 2019 | 72 | 2019 |
| TOPARP-B: A phase II randomized trial of the poly (ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage … J Mateo, N Porta, UB McGovern, T Elliott, RJ Jones, I Syndikus, C Ralph, ... Journal of Clinical Oncology 37 (15_suppl), 5005-5005, 2019 | 60 | 2019 |
| Characterizing CDK12-mutated prostate cancers P Rescigno, B Gurel, R Pereira, M Crespo, J Rekowski, M Rediti, ... Clinical Cancer Research 27 (2), 566-574, 2021 | 59 | 2021 |
| The molecular underpinnings of prostate cancer: impacts on management and pathology practice DN Rodrigues, G Boysen, S Sumanasuriya, G Seed, AMD Marzo, ... The Journal of pathology 241 (2), 173-182, 2017 | 51 | 2017 |
